Related Experiment Videos
Left ventricular dilatation after myocardial infarction: ACE inhibitors, beta-blockers, or both?
R L Anthonio1, D J van Veldhuisen, W H van Gilst
1Institute of Clinical Pharmacology, University of Groningen, and Department of Cardiology/Thorax Center, University Hospital Groningen, The Netherlands.
Insights
Left ventricular dilatation after myocardial infarction (MI) predicts heart failure. Early intervention with angiotensin-converting enzyme (ACE) inhibition and beta-blockade can mitigate this remodeling process.
Area of Science:
- Cardiology
- Cardiovascular Research
- Heart Failure Pathophysiology
Background:
- Left ventricular (LV) dilatation following myocardial infarction (MI) is a critical determinant of patient prognosis and heart failure development.
- LV remodeling, characterized by dilatation, commences immediately post-MI and persists into the chronic heart failure phase.
Purpose of the Study:
- To discuss factors influencing LV remodeling after MI, including infarct size and neurohumoral activation.
- To evaluate the impact of interventions like thrombolysis, beta-blockade, and ACE inhibition on LV remodeling.
- To propose an early treatment strategy combining ACE inhibition and beta-blockade for post-MI patients.
Main Methods:
- Review of existing literature on factors affecting LV remodeling post-MI.
- Analysis of the effects of acute and chronic phase interventions on LV remodeling.
- Synthesis of evidence to propose a therapeutic strategy.
Main Results:
- Infarct size and neurohumoral activation (sympathetic and renin-angiotensin systems) are key modulators of LV remodeling.
- Reduction in infarct size and inhibition of neurohumoral pathways can positively influence remodeling.
- ACE inhibition and beta-blockade demonstrate beneficial effects in both acute MI and chronic heart failure settings.
Conclusions:
- A treatment strategy initiating both ACE inhibition and beta-blockade early after MI is proposed.
- Continued treatment in the chronic heart failure phase should be considered based on infarct size and ventricular function.
- Early and sustained pharmacological intervention can mitigate adverse LV remodeling post-MI.
Abstract:
Left ventricular (LV) dilatation after myocardial infarction (MI) is a major predictor of prognosis and identifies which patients will develop heart failure. Left ventricular dilatation or remodeling starts immediately after MI and progresses in the chronic phase of heart failure. Factors influencing remodeling, such as infarct size and neurohumoral activation, including the sympathetic and renin-angiotensin system, are discussed. Remodeling can be affected by reduction of infarct size and inhibition of neurohumoral activation. The effect of thrombolysis, beta-blockade, and angiotensin-converting enzyme (ACE) inhibition in the acute phase after MI and in the chronic phase of heart failure on remodeling are discussed. On the basis of beneficial effects of ACE inhibition and beta-blockade in acute MI and in chronic heart failure, a treatment strategy is proposed in which both ACE inhibition and beta-blockade are started early after MI. Depending on infarct size and ventricular function, continued treatment in the chronic phase of heart failure must be considered.